Tau Chimeras Do Make Fibrils—and a Chaperone Rips Them Apart
Inclusions in tau seed sensor cells are made of amyloid fibrils, say scientists at AD/PD 2023. In those cells, and in human neurons, a dis-aggregase shreds them.
ALL NEWS
6534 RESULTS
Sort By:
- Most Recent
- Most Commented
First Hit on Aggregated Tau: Antisense Oligonucleotide Lowers Tangles
Biogen/IONIS’s tau ASO BIIB080 dropped participants’ tau PET signal below baseline in six months of treatment, according to data from a Phase 1 study presented at AD/PD.
Macrophages Blamed for Vascular Trouble in ApoE4 Carriers
Perivascular macrophages both produce and react to the apolipoprotein, releasing toxic reactive oxygen species that constrict blood vessels.
Aduhelm Lowers Tau; Registry to Track Real-World Performance
While a death causes jitters, new blood phospho-tau data from Phase 3 trials strengthen the antibody’s claim to disease modification, and post-market studies seek evidence of benefit.
Scientists Ask What Plaque Clearance Means for the Long Haul
At AD/PD, scientists showed 3- and 4-year amyloid immunotherapy data hinting at sustained cognitive benefits. The number of remaining participants is tiny.
TREM2 Protects the Brain From Herpes. The Virus Fights Back.
The microglial receptor activates an antiviral signaling cascade. The virus downregulates TREM2 expression after infecting microglia.
Donanemab Mops Up Plaque Faster Than Aduhelm
In a head-to-head comparison, donanemab banished four times as much plaque in the first six months as aducanumab did, partly due to its faster titration.
Risk Gene Conspiracy: Clusterin Binds CD33, Souring Microglial Taste for Aβ
Clusterin latches onto dimers of CD33 on the microglial cell surface, setting off inhibitory signaling that squelched phagocytosis.
All Roads Lead to TREM2: Gearing Up to Target This Receptor
At AD/PD, scientists placed more AD genes into microglial pathways, homed in on how TREM2 gets cleaved, debuted TREM2 agonists, and unearthed potential biomarkers.
FDA Grants Accelerated Approval for Tofersen
The antisense oligonucleotide targets extremely rare variants of the superoxide dismutase 1 gene.
Paper Alert: Tau Antisense Oligonucleotide BIIB080 Hits Its Target
Safety and cerebrospinal fluid tau data from the six-month Phase 1 trial are now published.
With Microglia, It Takes a Village to Connect the Dots
Scientists showed how pooling microglia from different donors, then putting them through cutting-edge analyses, can link genetic variation to functional change.
International Conference on Alzheimer's and Parkinson's Diseases 2023
Pumping Up Progranulin: Scientists Show New Efforts to Get it Done First Hit on Aggregated Tau: Antisense Oligonucleotide Lowers Tangles Tau Chimeras Do Make Fibrils—and a Chaperone Rips Them Apart Macrophages Blamed for Vascular Trouble in ApoE4 Carriers
Long COVID and Dementia: The Link Is Still Elusive
While memory problems plague some people with lingering COVID symptoms, researchers do not yet understand what is going wrong in their brains.
Microglia Conflicted: To Help, or to Hinder, Tau’s March Across the Brain?
Data from TRIAD cohort cast activated microglia, egged on by ApoE4, as harbingers of tau pathology and neurodegeneration. Data from BioFinder hint that other microglia restrain these processes.
Current Filters
No filters selected